Patient-Derived Cancer Organoids for Precision Oncology Treatment.
Patient-Derived Cancer Organoids for Precision Oncology Treatment.
复制标题
DOI：
10.3390/jpm11050423
复制
发表时间：
2021-05-17
影响因子：
--
通讯作者：
Abdullah KG
中科院分区：
文献类型：
--
作者：
Pernik MN;Bird CE;Traylor JI;Shi DD;Richardson TE;McBrayer SK;Abdullah KG
三维人类类器官的出现为开发患者来源的癌症类器官（PDO）模型打开了大门，该模型紧密地再现了亲本肿瘤组织。临床前癌症建模的支柱包括体外细胞系和患者来源的异种移植物，但这些模型缺乏在人类肿瘤中观察到的细胞异质性。此外，异种移植物的建立是资源和时间密集型的，使得这些模型难以用于为临床试验和决策提供信息。然而，PDO可以有效地产生并保留肿瘤特异性特性，如细胞异质性、细胞-细胞和细胞-基质相互作用、肿瘤微环境和治疗反应性。PDO模型和药物筛选方案已被描述用于几种实体瘤，最近，用于神经胶质瘤。由于PDO可以在临床相关的时间范围内发展，并且具有母瘤的许多特征，因此它们可以增强为患者提供精确肿瘤护理的能力。这篇综述探讨了目前关于癌症类器官的文献，突出了PDO发展的历史，胶质瘤的类器官模型以及PDO的潜在临床应用。
The emergence of three-dimensional human organoids has opened the door for the development of patient-derived cancer organoid (PDO) models, which closely recapitulate parental tumor tissue. The mainstays of preclinical cancer modeling include in vitro cell lines and patient-derived xenografts, but these models lack the cellular heterogeneity seen in human tumors. Moreover, xenograft establishment is resource and time intensive, rendering these models difficult to use to inform clinical trials and decisions. PDOs, however, can be created efficiently and retain tumor-specific properties such as cellular heterogeneity, cell–cell and cell–stroma interactions, the tumor microenvironment, and therapeutic responsiveness. PDO models and drug-screening protocols have been described for several solid tumors and, more recently, for gliomas. Since PDOs can be developed in clinically relevant time frames and share many characteristics of parent tumors, they may enhance the ability to provide precision oncologic care for patients. This review explores the current literature on cancer organoids, highlighting the history of PDO development, organoid models of glioma, and potential clinical applications of PDOs.
登录
查看更多内容
影响因子：
48
作者：
Bian S;Repic M;Guo Z;Kavirayani A;Burkard T;Bagley JA;Krauditsch C;Knoblich JA
通讯作者：
Knoblich JA
DOI：
10.1056/nejmoa1407279
发表时间：
2015-06-25
期刊：
The New England journal of medicine
影响因子：
--
作者：
Eckel-Passow JE;Lachance DH;Molinaro AM;Walsh KM;Decker PA;Sicotte H;Pekmezci M;Rice T;Kosel ML;Smirnov IV;Sarkar G;Caron AA;Kollmeyer TM;Praska CE;Chada AR;Halder C;Hansen HM;McCoy LS;Bracci PM;Marshall R;Zheng S;Reis GF;Pico AR;O'Neill BP;Buckner JC;Giannini C;Huse JT;Perry A;Tihan T;Berger MS;Chang SM;Prados MD;Wiemels J;Wiencke JK;Wrensch MR;Jenkins RB
通讯作者：
Jenkins RB
影响因子：
64.5
作者：
Cheung KJ;Gabrielson E;Werb Z;Ewald AJ
通讯作者：
Ewald AJ
影响因子：
5.4
作者：
Bolck, Hella A.;Corro, Claudia;Moch, Holger
通讯作者：
Moch, Holger
影响因子：
16.6
作者：
Calandrini, Camilla;Schutgens, Frans;Drost, Jarno
通讯作者：
Drost, Jarno